| Browse All

Tiziana Life Sciences Ltd (TLSA)

Healthcare | Biotechnology | London, United Kingdom | NasdaqCM
1.24 USD -0.10 (-7.463%) ⇩ (April 17, 2026, 4 p.m. EDT)
After hours: 1.28 +0.04 (3.194%) ⇧ (April 17, 2026, 7:31 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 3:26 p.m. EDT

TLSA appears to be a high-risk, speculative play with significant volatility and weak fundamentals. The recent news about clinical trials and fundraising efforts may provide short-term momentum, but the lack of consistent earnings and dividend history makes it unsuitable for long-term investment. The options market suggests potential for a strong upward move, but the low liquidity and poor financials make it a risky proposition for most investors.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.138928
AutoETS0.149021
AutoARIMA0.149432
AutoTheta0.186516

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 50%
H-stat 3.86
Ljung-Box p 0.000
Jarque-Bera p 0.120
Excess Kurtosis -0.09
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.163
Market Cap 157,786,784
Forward P/E -6.20
Beta 0.37
Previous Name Tiziana Life Sciences PLC
Website https://www.tizianalifesciences.com

As of April 11, 2026, 3:26 p.m. EDT: The options activity indicates a strong bias towards calls, particularly for strikes significantly above the current price. The high open interest and volume for out-of-the-money (OTM) calls, especially for the June 18 expiration, suggest that speculators are anticipating a substantial upward move. The low implied volatility (IV) for puts suggests less bearish sentiment. However, the overall market fundamentals are weak, with negative earnings and low liquidity, which could limit the upside potential.


Info Dump

Attribute Value
52 Week Change 0.097345114
Address1 14/15 Conduit Street
All Time High 12.17
All Time Low 0.41
Ask 1.28
Ask Size 1
Average Daily Volume10 Day 199,160
Average Daily Volume3 Month 177,030
Average Volume 177,030
Average Volume10Days 199,160
Beta 0.373
Bid 1.21
Bid Size 1
Book Value 0.077
City London
Compensation As Of Epoch Date 1,735,603,200
Country United Kingdom
Crypto Tradeable 0
Currency USD
Current Price 1.24
Current Ratio 1.719
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.38
Day Low 1.22
Debt To Equity 1.163
Display Name Tiziana Life Sciences
Earnings Timestamp End 1,752,004,800
Earnings Timestamp Start 1,750,708,800
Ebitda -18,464,000
Ebitda Margins 0.0
Enterprise To Ebitda -7.593
Enterprise Value 140,197,776
Eps Current Year -0.133
Eps Forward -0.2001404
Eps Trailing Twelve Months -0.12
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.3228
Fifty Day Average Change -0.08280003
Fifty Day Average Change Percent -0.06259452
Fifty Two Week Change Percent 9.734511
Fifty Two Week High 2.6
Fifty Two Week High Change -1.3599999
Fifty Two Week High Change Percent -0.5230769
Fifty Two Week Low 1.01
Fifty Two Week Low Change 0.23000002
Fifty Two Week Low Change Percent 0.2277228
Fifty Two Week Range 1.01 - 2.6
Financial Currency USD
First Trade Date Milliseconds 1,542,724,200,000
Float Shares 64,808,990
Forward Eps -0.2001404
Forward P E -6.1956506
Free Cashflow -3,856,625
Full Exchange Name NasdaqCM
Full Time Employees 9
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.43948
Held Percent Institutions 0.03145
Implied Shares Outstanding 127,247,402
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,735,603,200
Last Split Date 1,596,153,600
Last Split Factor 2,499:1000
Long Business Summary Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Long Name Tiziana Life Sciences Ltd
Market us_market
Market Cap 157,786,784
Market State CLOSED
Max Age 86,400
Message Board Id finmb_261234197
Most Recent Quarter 1,751,241,600
Name Change Date 2,026-04-18
Net Income To Common -12,841,000
Next Fiscal Year End 1,767,139,200
Non Diluted Market Cap 157,786,777
Number Of Analyst Opinions 1
Open 1.35
Operating Cashflow -8,749,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 44 20 7495 2379
Post Market Change 0.039600015
Post Market Change Percent 3.1935496
Post Market Price 1.2796
Post Market Time 1,776,468,666
Prev Name Tiziana Life Sciences PLC
Previous Close 1.34
Price Eps Current Year -9.323308
Price Hint 4
Price To Book 16.103897
Profit Margins 0.0
Quick Ratio 1.649
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.1
Regular Market Change Percent -7.46269
Regular Market Day High 1.38
Regular Market Day Low 1.22
Regular Market Day Range 1.22 - 1.38
Regular Market Open 1.35
Regular Market Previous Close 1.34
Regular Market Price 1.24
Regular Market Time 1,776,456,000
Regular Market Volume 325,752
Return On Assets -0.83782
Return On Equity -2.32311
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 127,247,401
Shares Percent Shares Out 0.0114
Shares Short 1,456,539
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 1,529,567
Short Name Tiziana Life Sciences Ltd
Short Percent Of Float 0.0171
Short Ratio 10.02
Source Interval 15
Symbol TLSA
Target High Price 8.018026
Target Low Price 8.018026
Target Mean Price 8.018026
Target Median Price 8.018026
Total Cash 7,251,000
Total Cash Per Share 0.061
Total Debt 107,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.12
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.6664
Two Hundred Day Average Change -0.42639995
Two Hundred Day Average Change Percent -0.25588092
Type Disp Equity
Volume 325,752
Website https://www.tizianalifesciences.com
Zip W1S 2XJ